Skip to main content
main-content

18-05-2022 | Oncology | Video

ELCC 2022 | Neoadjuvant osimertinib shows promise for EGFR-mutated NSCLC

Chao Lyu discusses the final efficacy and safety results from the NEOS trial, demonstrating the benefits of osimertinib for EGFR-mutated resectable stage II–IIIB lung adenocarcinoma in the neoadjuvant setting (4:03).